Inflammatory bowel disease (IBD) is a chronic relapsing condition affecting the gastrointestinal tract and presenting with digestive disorders and inflammation in the digestive system that can result from ulcerative colitis or Crohn’s disease.

Current treatments for IBD include biological medicines (biologics), which are agents derived from living systems. However, their high cost has formed a barrier to treatment access for many patients, generating the need for biosimilars. This course will provide an overview of the latest clinically relevant information on the use of biosimilars in IBD. 

This 60-minute course has been designed for healthcare providers.

This course has a 2-year expiry date of 25th March 2026. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed.

CME/CPD Information

This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®).

This accreditation certifies the quality and relevance of the educational content.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

This course is also available on myCME: https://www.mycme.com/courses/fast-facts-biosimilars-in-inflammatory-bowel-disease-9379